04:40 AM EST, 12/05/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved Leqembi for the treatment of early Alzheimer's disease.

The approval is based on a phase 3 study, which met its primary endpoint and all key endpoints with statistically significant results, the company said.

Eisai and Biogen will co-commercialize and co-promote Leqembi, or lecanemab, in Mexico.